


What is claimed is:

- 1 1. A compound selected from the group consisting of (a) an isolindoline of the for-
- 2 mula:
- 3



- 4 wherein:
- 5 the carbon atoms designated \* constitute centers of chirality;
- 6 X is -C(O)- or -CH₂-;
- 7 R¹ is alkyl of 1 to 8 carbon atoms or -NHR³;
- 8 R² is hydrogen, alkyl of 1 to 8 carbon atoms, or halogeno; and
- 9 R³ is hydrogen,
- 10 alkyl of 1 to 8 carbon atoms, unsubstituted or substituted with alkoxy of 1 to
- 11 8 carbon atoms, halo, amino, or alkylamino of 1 to 4 carbon atoms,
- 12 cycloalkyl of 3 to 18 carbon atoms,
- 13 phenyl, unsubstituted or substituted with alkyl of 1 to 8 carbon atoms, alk-
- 14 oxy of 1 to 8 carbon atoms, halo, amino, or alkylamino of 1 to 4 carbon
- 15 atoms,
- 16 benzyl, unsubstituted or substituted with alkyl of 1 to 8 carbon atoms, alk-
- 17 oxy of 1 to 8 carbon atoms, halo, amino, or alkylamino of 1 to 4 carbon
- 18 atoms, or
- 19 -COR⁴ in which
- 20 R⁴ is hydrogen,

1                   alkyl of 1 to 8 carbon atoms, unsubstituted or substituted with  
2                   alkoxy of 1 to 8 carbon atoms, halo, amino, or alkylamino of 1  
3                   to 4 carbon atoms,  
4                   cycloalkyl of 3 to 18 carbon atoms,  
5                   phenyl, unsubstituted or substituted with alkyl of 1 to 8 carbon  
6                   atoms, alkoxy of 1 to 8 carbon atoms, halo, amino, or alkyl-  
7                   amino of 1 to 4 carbon atoms, or  
8                   benzyl, unsubstituted or substituted with alkyl of 1 to 8 carbon  
9                   atoms, alkoxy of 1 to 8 carbon atoms, halo, amino, or alkyl-  
10                  amino of 1 to 4 carbon atoms,  
11                  and  
12                  (b) the acid addition salts of said isoindoline which are susceptible of protonation.  
13                  2. A compound according to Claim 1 in which in said isoindoline derivative R<sup>2</sup> is  
14                  hydrogen, methyl, or fluoro.  
15                  3. A compound according to Claim 2 in which R<sup>2</sup> is hydrogen.  
16                  4. A compound according to Claim 3 in which said isoindoline derivative R<sup>1</sup> is  
17                  amino.  
18                  5. A compound according to Claim 4 in which said isoindoline derivative X is -C(O).  
19                  6. A compound according to Claim 4 in which said isoindoline derivative X is -CH<sub>2</sub>-.  
20                  7. A compound according to Claim 3 in which said isoindoline derivative R<sup>1</sup> is  
21                  methyl.  
22                  8. A compound according to Claim 2 in which said isoindoline derivative X is -C(O)-.  
23                  9. A compound according to Claim 2 in which said isoindoline derivative X is -CH<sub>2</sub>-.  
24                  10. The compound according to Claim 1 which is 2-(2,6-dioxo-3-hydroxypiperidin-5-  
25                  yl)-4-aminoisoindoline-1,3-dione.  
26                  11. The compound according to Claim 1 which is 2-(2,6-dioxo-3-hydroxypiperidin-5-  
27                  yl)-4-aminoisoindolin-1-one.

- 1    12. The compound according to Claim 1 which is 2-(2,6-dioxo-3-hydroxypiperidin-5-  
2        yl)-4-methylisoindoline-1,3-dione.
- 3    13. The compound according to Claim 1 which is 2-(2,6-dioxo-3-hydroxypiperidin-5-  
4        yl)-4-methylisoindolin-1-one.
- 5    14. A method of reducing or inhibiting undesirable levels of TNF $\alpha$  in a mammal  
6        which comprises administering thereto an effective amount of a compound  
7        according to Claim 1.
- 8    15. A method of treating in a mammal a disease selected from the group consisting  
9        of inflammatory disease, autoimmune disease, arthritis, rheumatoid arthritis,  
10      inflammatory bowel disease, Crohn's disease, aphthous ulcers, cachexia, graft  
11      versus host disease, asthma, adult respiratory distress syndrome, and acquired  
12      immune deficiency syndrome, which comprises administering thereto an effective  
13      amount of a compound according to Claim 1.
- 14    16. A method of treating cancer in a mammal which comprises administering  
15      thereto an effective amount of a compound according to Claim 1.
- 16    17. A method of treating undesirable angiogenesis in a mammal which comprises  
17      administering thereto an effective amount of a compound according to Claim 1.
- 18    18. A pharmaceutical composition comprising (i) a quantity of a compound accord-  
19      ing to Claim 1 that upon administration in a single or multiple dose regimen is  
20      pharmaceutically effective and (ii) a pharmaceutically acceptable carrier therefor.